ArticleFrontiers in endocrinology2025
Single-cell and transcriptomic analyses reveal the role of PCDH17 in the non-inflammatory tumor microenvironment of pancreatic cancer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pro-tumorigenic role of protocadherin 17 and its prognostic significance in Ewing sarcoma.Discover oncology · 2026Article
- The Multi-Target lncRNA-miRNA-mRNA TRIAD in Pancreatic Cancer Diagnosis and Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The PCDH17 family has emerged as a prominent research focus in the field of oncology; however, the precise mechanism underlying the regulatory role of PCDH17 in shaping the inflammatory tumor microenvironment in pancreatic cancer remains elusive. Method: A thorough examination was carried out to explore the presence of PCDH17 in cancerous tumor tissues and its association with genes related to inflammation. Additionally, we comprehensively examined the association between PCDH17 and immune cell infiltration as well as immunotherapy in pancreatic cancer. Moreover, the single-cell data of pancreatic cancer was utilized for analyzing PCDH17 expression, cell differentiation, and intercellular communication. Result: PCDH17 exhibited differential expression across various tumor types. The low-expression group of PCDH17 showed reduced levels of inflammatory genes. Immunoinfiltration analysis indicated a significant association between T-cell infiltration and the expression of PCDH17. Analysis of single-cell sequencing data revealed that PCDH17 was primarily expressed in endothelial cells, with a decrease in expression observed during cellular differentiation trajectory. Notably, inflammation-related genes also displayed significant changes in their expression patterns along the endothelial cell differentiation trajectory. Cellular communication investigations unveiled multiple signaling pathways through which endothelial cells interacted with T cells. The presence of PCDH17 in endothelial cells was verified through various immunofluorescence techniques, and a simultaneous decline in its levels was observed alongside the decrease in inflammatory factors within the tumor microenvironment. Conclusion: The predominant expression of PCDH17 was observed in endothelial cells, exhibiting a strong association with inflammatory genes and infiltration of immune cells. PCDH17 exhibits potential as a target for regulating the immune-suppressive tumor microenvironment in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.